Clinical Trial · NCT01881451

Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer

Overview

The purpose of this study is to use 18F-EF5 PET/CT scans to locate areas with low oxygen levels (hypoxia) in patients with recurrent and/or metastatic cancer.

Sponsor

British Columbia Cancer Agency

Contacts

Anna Tinker, MD, FRCPC (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01881451

Drug / Compound

EF5

Isotope(s):

Target(s):

Hypoxia

Ligand Class: Small Molecules

Eligibility

Inclusion

Must be able to provide written informed consent, and willing to comply with protocol procedures of the study
* Histologically confirmed, advanced metastatic or recurrent clear cell cancer of the ovary
Off all active therapy for at least 4 weeks (cytotoxic chemotherapy, radiation, immune therapy, hormone therapy, clinical trials or new agents)
At least one index lesion measuring 2 cm in diameter

Exclusion

Previous history of cancer, except treated non-melanoma skin cancer, non-invasive breast cancer, non-invasive cervical cancer; or curatively treated solid cancer with no evidence of recurrence for more than 5 years.
* Renal failure (eGFR \< 50mls/min)
Receiving or had received active therapy in the form or chemotherapy or radiation within 4 weeks of the PET scan
Patients with unknown primaries
ECOG status ≥ 3